Maxwellia builds team to deliver OTC switches

Maxwellia builds team to deliver OTC switches
Alexandra Trehane (pictured top) is Maxwellia's head of innovation, while Emma Quaranta (pictured bottom) is senior regulatory consultant

7 November 2018 - Deborah Wilkes

Maxwellia – which describes itself as the "UK's only prescription to OTC medicines company" – has hired a head of innovation and a senior regulatory consultant.

The company has recruited Alexandra Trehane as head of innovation. She was previously regulatory manager at GlaxoSmithKline Consumer Healthcare.

Emma Quaranta – formerly regulatory affairs officer at Bell’s Healthcare – has been appointed senior regulatory consultant.

Maxwellia said Trehane and Quaranta brought "significant OTC experience from their previous roles".

Rapid growth phase

The UK-based company, which recently relocated to the Alderley Park Accelerator near Manchester, added the appointments were "part of a rapid growth phase for the company" and would "expedite conversion of prescription medicines to OTC".

Commenting on the appointments, Maxwellia's chief executive officer, Anna Maxwell, said: "Growing our team and expert capability will allow us to focus on speed-to-market for our new products, enabling more people to access the information and medicines they need without having to bother their general practitioner."

Speaking to OTCToolbox in April 2018, Maxwell said the company planned to build a pipeline of switches that would either be commercialised by Maxwellia or offered to third parties as a turnkey "switch in a box" product.

"We are trying to make switching simpler, faster and cheaper with a greater chance of success," commented Maxwell, adding the company wanted to "bring step-changing innovation to the OTC market".

Initially focusing on the UK market

Maxwellia would initially focus on the UK market, she said, but the switch specialist planned to extend into other countries in the longer-term.

"Switching is a vital means of maintaining the flow of new drugs for self-care," said Maxwell, "and it is estimated that new switches could add 20% to the UK OTC market by 2030."

Maxwellia has raised early-stage investment worth GBP0.70 million (USD0.92 million) to fund its ambitious programme of switching medicines from prescription-to-OTC status (click here to read the News story).

In addition to switching medicines from prescription-to-OTC status, Maxwellia offers "consultancy and capability services to small and mid-sized pharmaceutical companies".

Click here to contact Anna Maxwell by email.

Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions

Back to Industry News

Share this page: